[Promising treatment of neovascular age-related macular degeneration is coming. But to what price?].
Frennesson
Christina
C
Ogonkliniken, Universitetssjukhuset i Linköping. Christina.Frennesson@lio.se
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D016527:Drug Costs; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D012449:Safety; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab